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Background. Experimental research in hepatology has focused on developing traditional medicines into potential pharmacological
solutions aimed at protecting liver from cirrhosis. Along the same line, this study investigated the eﬀects of ethanol-based
extract from a traditional medicine plant Boesenbergia rotunda (BR) on liver cirrhosis. Methodology/Results. The BR extract was
tested for toxicity on 3 groups of rats subjected to vehicle (10% Tween 20, 5mL/kg) and 2g/kg and 5g/kg doses of the extract,
respectively. Next, experiments were conducted on a rat model of cirrhosis induced by thioacetamide injection. The rats were
divided into five groups and, respectively, administered orally with 10% Tween-20 (5mL/kg) (normal control group), 10% Tween-
20 (5mL/kg) (cirrhosis control group), 50 mg/kg of silymarin (reference control group), and 250mg/kg and 500mg/kg of BR
extract (experimental groups) daily for 8 weeks. The rats in normal group were intraperitoneally injected with sterile distilled water
(1mL/kg) 3 times/week, and those in the remaining groups were injected intraperitoneally with thioacetamide (200 mg/kg) thrice
weekly. At the end of the 8 weeks, the animals were sacrificed and samples were collected for comprehensive histopathological,
coagulation profile and biochemical evaluations. Also, the antioxidant activity of the BR extract was determined and compared
with that of silymarin. Data from the acute toxicity tests showed that the extract was safe to use. Histological analysis of the livers
of the rats in cirrhosis control group revealed uniform coarse granules on their surfaces, hepatocytic necrosis, and lymphocytes
infiltration. But, the surfaces morphologically looked much smoother and the cell damage was much lesser in those livers from
the normal control, silymarin and BR-treated groups. In the high-dose BR treatment group, the livers of the rats exhibited nearly
normal looking lobular architecture, minimal inflammation, and minimal hepatocyte damage, the levels of the serum biomarkers
and liver enzymes read nearly normal, and these results were all comparable to those observed or quantified from the normal and
silymarin-treated groups. The BR extract had the antioxidant activity about half of what was recorded for silymarin. Conclusion.
The progression of the liver cirrhosis can be intervened using the ethanol-based BR extract, and the liver’s status quo of property,
structure, and function can be preserved. This capability of the extract warrants further studies exploring the significance of its
pharmacologic potential in successfully treating the liver cirrhosis in humans.
1. Introduction
Pharmaceutical compounds with formulations based on
interferon, colchicines, penicillamine, and corticosteroids are
currently available for treating common liver diseases of
cirrhosis, fatty liver, and chronic hepatitis, but with either
inconsistent eﬃcacies or high incidences of side eﬀects [1].
A number of natural compounds extracted from plants
oﬀer alternative treatment options that are safe and eﬀective
[2]. Extracts from newly discovered or already known plant
species are constantly being tested on animal model systems
mimicking human diseases and injuries [3]. Presently, many
natural extracts are used for treating human disorders in
organs, but other than the liver [4]. Therefore, the potential
roles and eﬀectiveness of these extracts in liver diseases are yet
to be studied. An extract obtained from the perennial herb
Boesenbergia rotunda (BR) is one of those in this category
and waiting for exploration of its role in liver pathologies.
The plant BR belongs to the family Zingiberaceae and
is traditionally called temu kunci. With unique finger-like
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rhizomes, it is commonly used as a folk medicine in South-
east Asia for treating several diseases including aphthous,
dry mouth, stomach discomfort, leucorrhea, and dysentery.
Scientific investigations in the past have reported that the
extracts isolated from the BR plant using various solutions
(such as methanol, hexane, or chloroform) have neuro-
protective [5], antibacterial [6], anticancer [7], antifeedant
[8], and antiviral [9] eﬀects. The methanol-based extract
was shown to contain chemical compounds Quercetin
and Kaempferol, which are known to play critical role in
antioxidant and anti-inflammatory cascades or processes
[10]. When the hexane or chloroform is used in the isolation
process, the resulting extract contains other important anti-
oxidants: three flavanones (pinostrobin, pinocembrin, and
alpinetin) and two chalcones (cardamonin and boesenber-
gin) [11].
Our laboratory has been investigating the therapeutic
values of various plant-based extracts in prevention and
protection of liver against toxins [12]. As a continuation of
our eﬀorts, in this study, for the first time, we evaluated
the previously demonstrated anti-oxidant property of the
ethanol-based BR extract in progressive liver damage. In
particular, we tested the eﬃcacy of the extract as a therapeutic
agent on a rat model of liver cirrhosis induced chemically by
thioacetamide (TAA) administration. We have been working
with this experimental model because it closely mimics the
etiology and pathology of the disease seen in humans.
To objectively evaluate the therapeutic value of the BR
extract on the liver cirrhosis, we also employed another
herbal substance silymarin—a hepatoprotectant with a well-
established record [13]. Silymarin is a purified extract
obtained from the seeds of the plant Silybum marianum
and used widely as a supportive therapy for liver disorders
such as cirrhosis, hepatitis, and fatty acid infiltration due to
alcohol and toxic chemicals [14]. We compared the positive
eﬀects achieved with the BR extract on the cirrhotic liver
against the benchmark protection provided by silymarin.
In the following, we describe each of the processes and
procedures employed in our experiments for assessing the
anti-oxidant power, toxicity, and eﬀectiveness of the BR
extract. We present extensive data showing pathological and
biochemical changes obtained with and without the extract
treatment in groups of experiments and discuss our findings
in detail regarding the merit of theBR extract as a potential
agent for protecting the liver from cirrhosis.
2. Materials and Methods
2.1. Experimental Animals. Animal protocols governing
the experiments were approved by the Ethics Commit-
tee for Animal Experimentation, Faculty of Medicine,
University of Malaya, Malaysia and the Ethic number
PM/07/05/2010/MMA (a) (R) and PM/28/08/2010/MAA
(R). Sprague Dawley rats of 6–8 weeks old and weighed
between 180 and 200 g were obtained from the institu-
tional animal facility. Throughout the study, the rats were
cared humanely and maintained for their normal circadian
rhythms by following the guidelines provided in the “Guide
for the Care and Use of laboratory Animals” which was
prepared by the National Academy of Sciences and published
by the National Institute of Health, Malaysia. The rats were
given standard pellet diet and tap water, kept in wire-
bottomed cages at 25 ± 2◦C, exposed to 12 hours light and
dark cycle, and housed in an animal room with 50–60%
humidity range.
The study was performed in three phases. The first phase
involved removing the extract from the BR plant rhizomes
and measuring its anti-oxidative property. In the second
phase, the toxicity of the extract was examined on 36 (18
males and 18 females) healthy Sprague Dawley rats. In the
third phase, the eﬃcacy of the extract on inhibiting the
development of liver cirrhosis was evaluated using 30 healthy
adult male Sprague Dawley rats weighing 200–240 g. This
experimental phase required chemically inducing cirrhosis
by TAA injection to the rats and also using another plant
extract silymarin for a reference comparison.
2.2. Extract Removal from the Plant BR. Fresh rhizomes of
the plant BR were purchased from a commercial company
(Ethno Resources Sdn Bhd, Selangor, Malaysia), and identi-
fied by comparing it with the voucher specimen deposited at
the Herbarium of Rimba Ilmu, Institute of Science Biology,
University of Malaya, Kuala Lumpur, Malaysia. After washing
with tap water first and then distilled water later, the
rhizomes were sliced and left in a shade for a duration of 10
days to dry out. The dried samples were then grounded finely,
and 100 g of the resulting powder was mixed in 1000mL
solution of 95% ethanol for 7 days at room temperature.
The ethanol extract was distilled under a reduced pressure
in Eyela Rotary Evaporator (Sigma-Aldrich, USA), and dried
at 40◦C in an incubator for 3 days giving a gummy yield
of 9.49% (w/w). For the oral administration to the rats, the
final product was further dissolved in Tween 20 (10% w/v)
and the desired dose for the administration was expressed as
concentration in mg/mL per body weight in kg.
2.3. Antioxidant Power of the BR Extract. The anti-oxidant
power of the BR extract was determined using a test sensitive
to its scavenging ability towards reactive oxygen species or
reagents containing iron. In this regard, the ferric reducing
anti-oxidant power (FRAP) of the BR extract was determined
using an assay by following the method described in
[15], but with a slight modification. The FRAP reagent
was prepared by mixing 300mM acetate buﬀer (3.1mg
sodium acetate/mL, pH 3.6), 10mM 2,4,6-tripyridyl-S-
triazine (TPTZ) (Merck, Darmstadt Germany) solution and
20mM FeCl3·H2O (5.4mg/mL). The BR extract and the
following standards: Gallic acid, Quercetin, Ascorbic acid,
Rutin, Trolox, and 2,6-di-tert-butyl-4-methyl phenol (BHT),
were sampled in amounts of 10 μL of 1mg/mL and 10 μL
each along with 10 μL of 0.1mg/mL silymarin. To each sam-
ple separately, 290 μL of the reagent TPTZ were added. The
absorbencies of the resulting mixtures were read repetitively
at every 4min for up to 2 hr using ELISA reader (Shimadzu,
The Netherlands) at 593 nm wavelength. We note that the
dynamic range of the instrument was limited to read the
Evidence-Based Complementary and Alternative Medicine 3
dose amounts of 500mg/kg for the BR extract and 50mg/kg
dose for silymarin administered to the rats daily, as described
below. To compensate this deficiency, we performed the
measurements in equivalent amounts obtained by scaling the
administered doses up by 20 times, respectively. The readings
from the mixtures containing the BR extract and silymarin
were compared against the following standards: Gallic acid,
Quercetin, Ascorbic acid, Rutin, Trolox, and BHT (2,6-di-
tert-butyl-4-methyl phenol) [14].
2.4. Toxicity of the BR Extract. The toxicity of the BR extract
was evaluated in normal healthy rats by subjecting them
significantly to high doses of the extract. Rats were assigned
equally into 3 groups, each with 6 males and 6 females,
labeled as vehicle (10% Tween-20, 5mL/kg) and 2 g/kg and
5 g/kg of rhizome extract preparation, respectively. The rats
were deprived of food but not water prior to the dosing. Food
was withheld for another 3-4 hours after the dosing. The
animals were observed at 30min and 2, 4, 8, 24, and 48 hours
after the oral administration to detect the onset of clinical or
toxicological symptoms. The animals were sacrificed on day
15. Through the jugular vein, blood was collected directly at
the time of the sacrifice. Histological Prothrombin time and
serum biochemical parameters were determined following
the standard methods [16].
2.5. Treatment Groups and Experiments. A set of experiments
were carried out to test the therapeutic eﬀects of the BR
extract on liver cirrhosis. For this purpose, thirty male rats
were acquired and randomly divided into 5 groups where
each consisted of 6 rats. The experiments lasted for 8 weeks,
and all of the rats were kept alive during this timeframe.
Classifications of the groups were as follows.
Group 1 served as the normal control group. The rats
in this group were administered orally with 10% Tween-
20 (5mL/kg) daily and injected intraperitoneally (IP) with
sterile distilled water (1mL/kg) thrice weekly.
The rats in the remaining Groups 2–5 were exposed
to Thioacetamide (TAA) toxicity to induce cirrhosis in
their livers. Constant exposure with this amount of TAA
induces changes in liver pathology from both biological
and morphological aspects comparable to the etiology of
cirrhosis seen in humans [17] and therefore used very
often as a preferred model in experimental studies of liver
cirrhosis. Highest grade of TAA was purchased in crystal
form from Chemolab Supplies, (Sigma-Aldrich, USA). The
crystals were diluted in sterile distilled water and stirred
well until all fully dissolved to prepare a stock solution of
5 g/L. TAA was injected IP three times a week at a dose of
(200mg/kg/mL in distilled water) [18].
Group 2 served as the cirrhosis control group with
cirrhotic rats injected IP with TAA three times a week at a
dose of (200mg/kg/mL in distilled water) and oral delivery
of 10% Tween 20 (5mL/kg) daily.
Group 3 was the silymarin-treated group. The cirrhotic
rats in this group were administered orally with silymarin
(50mg/kg) daily. Silymarin (International Laboratory, USA)
is a standard drug and was prepared by dissolving in 10%
Tween 20 [19].
Groups 4 and 5 were the treatment groups, where the
cirrhotic rats were administered orally with the BR extract
at respectively 250mg/kg and 500mg/kg doses daily.
We rationalized that the above protocol of applying
treatment with silymarin or the BR extract in parallel
after inducing cirrhosis using TAA injection was clinically
equivalent to instituting the therapy as soon as the onset of
the cirrhosis was diagnosed. In this regard, the treatment
is preventive since it slows down the progression of the
cirrhosis and protective since the liver is protected from
further deterioration.
After 8 weeks, each rat was made to fast for 24 hours
after the last treatment and then perfused under Ketamine
(30mg/kg, 100mg/mL) and Xylazil (3mg/kg, 100mg/mL)
anesthesia [20]. Through the jugular vein, blood was with-
drawn and collected for prothrombin time and biochemical
examinations. After the perfusion, the liver was excised and
washed in ice-cold normal saline, blotted in filter paper,
weighed and carefully inspected for the presence of any gross
pathology. The liver tissues were further assessed as described
below.
2.6. Postmortem Liver Tissue Analysis. For the histopatholog-
ical analysis, the liver specimens were fixed in 10% buﬀered
formaldehyde, processed by automated tissue processing
machine, and then embedded in paraﬃn wax. Sections were
prepared in 5 μm thicknesses, stained with hematoxylin-
eosin (H&E), and examined under the light microscope.
For determining the normality of the hepatocytes, the
number of normal cells was counted at the center of the
cirrhotic area as well as the normal areas adjacent to both
sides of the cirrhotic area using a light microscope with
an oil immersion objective (×40) covering 0.15mm2 [21].
Percentage of the normal cells was calculated by using
the formula: %Normal cells = [(Normal cells/(Normal +
apoptotic cells) × 100].
2.7. Evaluation of Cellular Damage. Malondialdehyde
(MDA) is a natural product of lipid peroxidation after
cellular injury, and used as an indicator of cellular oxidative
stress [22]. Superoxide dismutase enzyme (SOD) plays
crucial role in defense mechanisms governing the anti-
oxidant activities and hence in prevention of diseases linked
to oxidative stress [23]. To examine the actions of the BR
extract on the levels of MDA and SOD in the livers of
the rats in all experimental Groups 1–5, the liver tissues
were extracted, washed in saline, homogenized (10% w/v)
in 50mM cold potassium phosphate buﬀer (pH 7.4) by
using tephlon homogenizer (Polytron, Heidolph RZR 1,
Germany), and processed at 3500 rpm for 10 minutes at 4◦C
in a centrifuge (Heraeus, Germany). The MDA level was
measured from the supernatant using thiobarbituric acid
as the lipid peroxidation marker [24]. Similarly, the SOD
activity was assessed based on a method described in [25].
2.8. Biochemical Analysis. On sacrifice, blood samples of
the rats were collected through the jugular vein into tubes
with sodium citrate for determining prothrombin time or
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into gel-activated tubes for the assessment of lipid profile
and biochemical markers such as alkaline phosphatase (AP),
alanine aminotransferase (ALT), aspartate aminotransferase
(AST), lactate dehydrogenase (LDH), total protein, albumen,
and bilirubin. The gel-activated tubes were allowed to clot,
centrifuged at 3000 rpm for 10 minutes at 4◦C. The serum
samples were used for measuring the liver biochemicals. The
markers were spectrophotometrically assayed by standard-
automated techniques using the equipment at the Central
Diagnostic Laboratory of the Medical Centre of University
Malaya.
2.9. Statistical Analysis. The measurements from the exper-
imental Groups 1–5 were evaluated statistically, and the
statistical diﬀerences between the groups were determined
using one-way ANOVA followed by Tukey Post-Hoc test
analysis using SPSS program (version 18, SPSS Inc., Chicago,
IL, USA). A value of P < 0.05 was considered as an
indicative of statistically significant diﬀerence between the
measurements of the two compared groups. All readings and
calculated values were reported as Mean ± SEM.
3. Results
3.1. Anti-Oxidant Property of the BR Extract. As shown
in Figure 1, the ferric reducing antioxidant power (FRAP)
of 1mg/mL of BR extract was measured as 288.9 ±
0.002mmol/1mg while the calibration curve equation was
y = 0.0006 + 0.065, R2 = 0.9976. The measured value
was relatively lower than those of the standards Gallic
acid, Quercetin, Ascorbic acid, Rutin, Trolox, and BHT, but
comparable to the reference drug silymarin, which read
600.6± 0.003mmol/0.1mg. Silymarin contains several anti-
oxidant compounds that play hepatoprotective roles. The
BR extract may be playing similar role as it has free radical
scavenging property and hence help the liver maintain its
status quo.
3.2. Acute Toxicity Test. All the rats in the acute toxicity
test remained alive and did not manifest mortality or any
visible signs of toxicity throughout the 15-days-long study
at the high doses of the BR extract 2 g/kg and 5 g/kg that
they were subjected to. The physical observations indicated
no signs of changes in their skins and furs, eyes and mucus
membranes, behavior patterns, tremors, salivations, diarrhea
occurrences, and sleeps. The body weight of the treated
male and female rats increased gradually but were not
significantly diﬀerent as compared to those of the control
rats. Gross necropsy findings did not reveal visible changes
in any of the organs. The clinical observations were that
serum biochemical measurements reflected the functional
status of normal kidney and liver, and the histopathological
evaluations of the kidney and the liver tissues all together
revealed that there were no significant diﬀerences between
the control and test groups, as shown by the quantitative data
in Tables 1 and 2, and qualitative data in Figure 2.
3.3. Eﬀects of the BR Extract on Liver Cirrhosis
3.3.1. Body Weight and Liver Index. The total body of each
rat was weighted prior to the sacrifice. Similarly, the liver
was weighted after being excised (Table 3). The control
rats in Groups 1 followed natural growth pattern and
attained normal weight gains from about 200 g to 347 g in
8 weeks. The injection of TAA made the rats hepatotoxic
(Group 2) and suﬀer growth retardation as they weighted
significantly less (mean = 217 g) than those measured from
the other groups. When the body weights were factored in,
the cirrhotic rats in Group 2 had the highest liver index
(mean = 5.27). The rats in the silymarin and high dose
(500mg/kg) BR treatments in Groups 3 and 5, respectively,
attained weights as equivalent as the normal rats in Group
1. The rats in the low-dose (250mg/kg) BR treatment Group
4 had better weight gain than those in Group 2, but not as
much as those attained in Groups 3 and 5.
These findings implied that the outcome of the treatment
was susceptible to the administered dose amount, but the
BR extract at this high-dose appeared to be optimal since it
was as eﬀective as silymarin in counteracting the progression
of cirrhosis. In light of this, we suggest administering
the 500mg/kg dose of the BR extract in strategizing any
treatment plan targeting to oﬀset cirrhosis in the future
experimental studies with translational focus.
3.3.2. Gross Anatomy and Histopathology. Figures 3 and 4,
respectively, depict the gross appearances and the H&E-
stained sections of the example liver samples from the
experimental Groups 1–5. Grossly, the livers from the control
rats in Group 1 (Figure 3(a)) appeared in reddish color, had
smooth surfaces, and did not show any sign of nodules. The
histological examination (Figure 4(a)) showed normal liver
architecture with normal plates of hepatocytes separated by
sinusoidal capillaries and central vein. In cirrhotic Group
2, the liver appeared congested with numerous micro- and
macronodules (Figure 3(b)), lost its normal architecture by
the presence of regenerating nodules that were separated
by fibrous septae extending from the central vein to portal
triad (Figure 4(b)). In addition, the fibrous septae were
accompanied by severe proliferation of bile duct and heavy
invasion of inflammatory cells. The cirrhotic nodules showed
thick purple-colored bundles of collagen fibers. The livers of
the reference control silymarin Group 3 (Figures 3(c) and
4(c)) and the high doses of BR extract (Figures 3(e) and 4(e))
showed a relatively minor micronodules, a lesser amount of
fibrous septae development and expansion and an increase
in the extension of normal hepatic parenchyma compared to
those from the reference Group 3. In contrast, the livers of the
low-dose BR Group 4 were occupied by lesser macronodules
and lesser fibrotic nodules than those of the reference Group
3, but the improvements were not as much as those seen in
Groups 3 or 5. These results based on the visual evaluations
provided further independent confirmation that the applied
BR extract was eﬀectively protecting the liver against the
progression of cirrhosis.
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Figure 1: Antioxidant activity of the BR extract compared with the following standards: Gallic acid, Quercetin, Ascorbic acid, Rutin, Trolox,
BHT as well as the standard drug Silymarin. Values were expressed as Mean ± SEM. Significant value was at P < 0.001.
Table 1: Renal function measured from the acute toxicity test of the BR extract on rats.
Dose Sodium (mmol/L) Potassium (mmol/L) Chloride (mmol/L) Urea (mmol/L) Creatinine (μmol/L)
Vehicle (5mL/kg) 138.25± 0.45 5.03 ± 0.19 104.03 ± 0.15 5.63 ± 0.41 50.18 ± 1.34
LD (2 g/kg) 137.65 ± 0.43 5.21 ± 0.16 102.61 ± 1.22 4.96 ± 0.43 48.97 ± 0.81
HD (5 g/kg) 137.21 ± 0.51 4.89 ± 0.15 102.67 ± 0.76 5.93 ± 0.39 48.60 ± 1.80
The values were expressed as mean ± S.E.M. There were no significant diﬀerences between the three groups. Significant value was at P < 0.05.
Table 2: Liver function measured from the acute toxicity test of the BR extract on rats.
Dose Total protein (g/L) Albumin (g/L) TB (μmol/L) AP (IU/L) ALT (IU/L) AST (IU/L) GGT (IU/L)
Vehicle (5mL/kg) 71.37 ± 1.44 11.36 ± 0.53 1.91 ± 0.17 134.78 ± 9.57 53.05 ± 3.27 153.65 ± 9.35 4.91 ± 0.93
LD (2 g/kg) 71.47 ± 0.52 11.61 ± 0.34 2.18 ± 0.16 133.37 ± 8.63 51.90 ± 1.33 156.07 ± 3.56 5.00 ± 1.23
HD (5 g/kg) 71.81 ± 1.03 11.72 ± 0.16 1.88 ± 0.21 135.13 ± 6.52 52.27 ± 3.25 155.00 ± 5.35 5.32 ± 1.07
TB: total bilirubin; AP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transferase. The values
were expressed as mean ± S.E.M. There were no significant diﬀerences between the three groups. Significant value was at P < 0.05.
Table 3: Liver index measurements from the rats at the end of the 8-week study.
Treatment Body weight (gm) Liver weight (gm) Liver index (LW/BW %)
Group 1 (normal rats) 347± 5.04 9.70± 0.16 2.79± 0.21
Group 2 (rats with cirrhosis) 183± 2.32 9.44± 0.60 5.18± 0.06∗∗
Group 3 (silymarin-treated rats) 347± 3.58 10.28± 0.66 2.97± 0.35∗
Group 4 (treatment with the BR extract at 250mg/kg dose) 255± 2.91 10.03± 0.46 3.93± 0.44∗
Group 5 (treatment with the BR extract at 500mg/kg dose) 376± 5.67 9.71± 0.71 2.59± 0.36∗
Data were expressed as Mean ± SEM. Means between the silymarin-treated Group 3, low-dose BR-treated Group 4, and high-dose BR-treated Group 5 had
significant diﬀerences when compared with the cirrhosis control Group 2 with ∗P < 0.001 and compared with the normal control Group 1 with ∗∗P < 0.001.
Table 4: Eﬀect of BR ethanol extract on plasma levels of specific liver enzymes at the end of the 8-week study.
Treatment AP IU/L ALT IU/L AST IU/L LDH IU/L
Group 1 (normal rats) 79.28± 0.58 30.57± 1.51 70.35± 0.21 490.97± 3.90
Group 2 (rats with cirrhosis) 270.50± 4.88∗∗ 150.42± 2.60∗∗ 250.88± 2.99∗∗ 991.72± 5.01∗∗
Group 3 (silymarin-treated rats) 83.85± 1.06 31.62± 0.63 70.35± 0.43 546.33± 10.46
Group 4 (treatment with the BR extract at 250mg/kg dose) 110.22± 0.49∗ 91.02± 1.61∗ 106.00± 2.59∗ 792.00± 3.51∗
Group 5 (treatment with the BR extract at 500mg/kg dose) 86.13± 0.56∗ 33.42± 0.56∗ 71.10± 0.78∗ 574.00± 5.34∗
AP: alkaline phosphatase; ALT: alanine transferase; AST: aspartate transferase; LDH lactate dehydrogenase. Means between the silymarin-treated Group 3, low-
dose BR-treated Group 4, and high-dose BR-treated Group 5 had significant diﬀerences when compared with the cirrhosis control Group 2 with ∗P < 0.001
and compared with the normal control Group 1 with ∗∗P < 0.001.
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Table 5: Eﬀect of Br ethanol extract on serum protein, albumen, and globulin levels and prothrombin time ratio at the end of the 8-week
study.
Treatment Protein g/L Albumen g/L Bilirubin umol/L Prothrombin time ratio
Group 1 (normal rats) 76.58± 0.70 31.93± 0.64 1.20± 0.06 1.02± 0.006
Group 2 (rats with cirrhosis) 59.92± 1.14∗∗ 11.22± 0.33∗∗ 4.98± 0.12∗∗ 1.38± 0.024∗∗
Group 3 (silymarin-treated rats) 75.82± 0.70 32.38± 0.88 1.28± 0.07 1.02± 0.005
Group 4 (treatment with the BR extract at 250mg/kg dose) 63.37± 1.20 20.20± 0.20∗ 2.85± 0.10∗ 1.28± 0.009∗
Group 5 (treatment with the BR extract at 500mg/kg dose) 75.10± 1.07∗ 29.38± 0.28∗ 1.68± 0.05∗ 1.03± 0.002∗
Means between the silymarin-treated Group 3, low-dose BR-treated Group 4, and high-dose BR-treated Group 5 had significant diﬀerences when compared
with the cirrhosis control Group 2 with ∗P < 0.001 and compared with the normal control Group 1 with ∗∗P < 0.001.
Table 6: Eﬀect of BR ethanol extract on serum lipid profiles at the end of the 8-week study.
Treatment Cholesterol mmol/L HDL mmol/L LDL mmol/L Triglycerides mmol/L
Group 1 (normal rats) 1.42± 0.05 1.13± 0.04 0.13± 0.02 1.27± 0.03
Group 2 (rats with cirrhosis) 3.22± 0.06∗∗ 0.53± 0.04∗∗ 2.50± 0.10∗∗ 2.83± 0.07∗∗
Group 3 (Silymarin-treated rats) 1.80± 0.04 1.32± 0.04 0.33± 0.03 1.45± 0.04
Group 4 (treatment with the BR extract at 250mg/kg dose) 2.00± 0.06∗ 0.62± 0.07 1.22± 0.07∗ 1.78± 0.03∗
Group 5 (treatment with the BR extract at 500mg/kg dose) 1.57± 0.05∗ 1.17± 0.05∗ 0.23± 0.02∗ 1.42± 0.05∗
Means between the silymarin-treated Group 3, low-dose BR-treated Group 4, and high-dose BR-treated Group 5 had significant diﬀerences when compared
with the cirrhosis control Group 2 with ∗P < 0.001 and compared with the normal control Group 1 with ∗∗P < 0.001.
3.3.3. Cell Loss and Survival. The results concerning the
normality of the hepatocytes were illustrated in Figure 5
for the rats in Groups 1–5. According to the data, the
administration of TAA has observed to significantly decrease
the number of normal liver cells from about 94% measured
from the livers of the normal rats in Group 1 to about 11%
measured from the livers of the cirrhotic rats in Group 2.
Hepatocytic fatty degeneration was also present. In the low
dose BR (250mg/kg) treatment Group 4, the population of
the normal cells was higher, about 71%. But, the treatment
with the high dose BR maintained much higher number
of normal cells, about 93%, which was nearly equal to
those obtained from the silymarin-treated rats in Group 3
and comparable in the same manner to the normal rats in
Group 1.
The loss of hepatocytes in the livers of the cirrhotic rats
was probed indirectly via lipid peroxidation with MDA and
anti-oxidant enzymatic activity with SOD, and the results
were plotted in Figures 6 and 7. The MDA level reads
relatively high value of 3.87 ± 0.08 nmol/mg protein in the
cirrhosis control group when compared with the reading
from the normal group 1.22 ± 0.08 nmol/mg protein. The
SOD readings followed this trend but inversely, meaning
that the cirrhotic rats in Group 2 had lower value of 9.80 ±
0.13 u/mg protein than 14.89 ± 0.28μ/mg protein from the
normals in Group 1. These results indicated the presence of
severely damaged cells in the cirrhotic livers. Treating the
cirrhotic rats with the BR extract has significantly helped
the survival of the hepatocytes as indicated by the reduced
MDA and increased SOD levels in both the low- and high-
dose groups, but the eﬀect was more pronounced in the latter
group. In the low- and high-dose groups, the MDA reads
2.08 ± 0.04 nmol/mg protein versus 1.60 ± 0.03 nmol/mg
protein, and SOD reads 12.03 ± 0.06 u/mg protein versus
14.17 ± 0.19 u/mg protein, respectively. The MDA and SOD
readings from the normal group were 1.22 ± 0.08 nmol/mg
protein and 14.89 ± 0.28 u/mg protein, respectively and
the corresponding values for the silymarin treated-group
were 1.86 ± 0.03 nmol/mg protein and 14.03 ± 0.18 u/mg
protein, respectively. These results collectively suggested that
the BR treatment provided a host environment favorable for
both preventing and protecting the hepatocytes from further
damage.
3.3.4. Liver Markers and Lipid Profiles. Liver function of each
rat was measured by determining the plasma levels of specific
liver enzymes and lipid profile, and the results were presented
in Tables 4, 5, and 6. According to the data in Tables 4 and
5, the TAA-induced liver damage significantly elevated the
levels of specific liver enzymes AP, ALT, AST, LDH, bilirubin
and prothrombin time ratio (P < 0.001) and significantly
declined the protein and albumin levels in the cirrhotic rats
of Group 2 as compared with those measured from all the
other groups. Similarly, the lipid profiles in the cirrhotic
rats altered significantly such that the cholesterol, LDL, and
triglycerides levels were higher, and the HDL level was lower
(Table 6). The high-dose BR (500mg/kg) treatment Group
5 resulted in the readings on the biochemical markers that
were comparable to those of the control Group 1 and the
silymarin-treated (50mg/kg) Group 3, and better than the
readings obtained from the treatment with the low-dose
BR (250mg/kg) Group 4. These data further supported the
qualitative gross anatomical, histopathological findings, the
quantitative cell counts, presented above, and demonstrated
that the eﬀects of the toxicity induced by TAA on the liver
function can eﬀectively be counterbalanced by the positive
eﬀects of the BR extract treatment, but in a dose-dependent
manner.
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Figure 2: Examples of H&E-stained histological sections of livers (left column) and kidneys (right column) obtained from the rats in the
acute toxicity test. Rat with the liver and kidney shown in (a) and (b) was treated with 5mL/kg vehicle (10% Tween 20). Rat with the liver
and kidney shown in (c) and (d) was treated with 2 g/kg (5mL/kg) dose of the BR extract. Rat with the liver and kidney shown in (e) and (f)
was treated with 5 g/kg (5mL/kg) dose of the BR extract. There was no significant diﬀerence in the structures of the liver and kidney between
the treatment and control groups.
4. Discussion
Liver cirrhosis has become a serious public health problem
because of the broader use of prescription drugs with side
eﬀects in modern life or the substance abuse. Consequently,
the current research has focused on understanding the
underlying metabolisms and subsequently finding new ther-
apeutic solutions to interrupt the signaling pathways and
minimize the damages inflicted on the liver [26]. Beyond
the strategies with synthetic pharmacology, the search also
pursues alternative approaches that rely on natural products.
Especially, it targets those plants in the folk medicine with
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Figure 3: Example images showing macroscopic appearances of the livers sampled from rats in diﬀerent experimental groups. (a) The
liver of a control rat exhibiting regular smooth surface. (b) The liver of a hepatotoxic rat depicting numerous irregular whitish micro- and
macronodular on its surface and a large area of ductular cholangiocellular proliferation (arrow) embedded within fibrosis. (c) The liver of a
hepatoprotective rat treated with silymarin showing normal smooth surface. (d) The liver of a rat treated with 250mg/kg of the BR extract
illustrating nearly smooth surface with fewer granules (arrow head). (e) The liver of a rat treated with 500mg/kg of the BR extract having
normal smooth surface.
known history or demonstrated potential of positive eﬀects
against the diseases of the liver or other organs [27]. To
aid these eﬀorts, in this study, we examined the potential
of ethanol-based extract from the plant BR as a promising
therapeutic agent for treating liver cirrhosis.
In phase 2 of our study, we tested the toxicity of
the BR extract. Our data in Figure 2 and Tables 1 and 2
showed that the extract at high doses caused no significant
pathological abnormalities in the liver and kidney, and the
clinical biochemistry readings remained within the normal
range. These results were in agreement with the previous
reports on the safety of consuming the BR extract [28].
In the next set of experiments, we examined the influence
of the BR extract on the course of the cirrhosis development.
The cirrhotic condition was induced by a prolonged expo-
sure to TAA.Manipulating the amount of TAA dose produces
diﬀerent grades of liver damage that may range from the
parenchymal cell necrosis and liver cell proliferation to the
production of pseudolobules and nodular cirrhosis, [29].
In this study, we have chosen 200mg/kg dose-administered
IP for 2 months because this protocol was reported to
yield etiology similar to the human cirrhosis in terms of
anatomical, structural, functional, and architectural tissue
characteristics as well as the readings on the common
biochemical markers [30]. The same was again reconfirmed
collectively by the qualitative ex vivo visualization of the
nodules in Figures 3 and 4, the quantitative data on the lower
body weights of the cirrhotic rats in Table 3, the biochemical
imbalances in the liver markers in Tables 4 and 5, and altered
lipid profiles in Table 6. Therefore, our experimental rat
model of cirrhosis was suitable for testing the eﬃcacy of
any applied preclinical therapy with a clinical translation in
focus.
The TAA action in the development of cirrhosis was
suggested to be multifaceted and to involve multiple mech-
anisms [19]. For example, TAA interferes with the RNA
transference from nucleus to cytoplasm via its metabolite
thioacetamide-S-oxide (TASO2). Concerning the hepato-
cytes, a compromise in the RNA transfer leads to hepatic
cell death via the processes of apoptosis and necrosis
[31]. Quantitative histopathological analysis indicated the
presence of severe hepatocellular loss since the percentage of
the viable cells were substantially lower 11% in the cirrhotic
rats in Group2 than 94% in normals in Group 1 (Figure 5).
Lipid peroxidation is also a common event in a toxic
phenomenon and causes cell death due to the degradation
of membrane lipids [32]. Through another pathway, the
TAA toxicity contributes to the liver damage by stimulating
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(d) (e)
Figure 4: Example histopathological sections of livers sampled from rats in diﬀerent experimental groups. (a) Normal histological structure
and architecture were seen in livers of the control rats. (b) Severe structural damage, formation of pseudolobules with thick fibrotic septa
and necrotic areas were present in the liver of the hepatotoxic rat. (c) Mild inflammation but no fibrotic septa was depicted in the liver of the
hepatoprotective rat treated with silymarin. (d) Partially preserved hepatocyte and architecture with small area of necrosis and fibrotic septa
existed in the liver of the rat treated with 250mg/kg of the BR extract. (e) Partially preserved hepatocyte and architecture with small areas of
mild necrosis were observed in the liver of the rat treated with 500mg/kg of the BR extract. (H&E stain original magnification 20x).
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Figure 5: Eﬀect of BR ethanol extract on % cell normality. Data are expressed as mean ± SEM. Means among groups (n = 6 rate/group)
show significant diﬀerence, ∗P < 0.001 compared to cirrhosis control group and ∗∗P < 0.001 compared to normal control group.
the production of excessive reactive oxygen species [33].
This eﬀect was recorded in Figures 6 and 7. The data
indicated that the hepatocytes were under oxidative stress,
lipid peroxidation was prevalent as reflected by the larger
MDA readings, and the anti-oxidant defense mechanism was
failed as hinted by the attenuated SOD readings.
The cirrhotic livers responded favorably to the treat-
ment with the BR extract at both doses (250mg/kg and
500mg/kg) and the reference extract silymarin at the daily
dose of 50mg/kg. Each of the treatment regimens unequivo-
cally produced significant improvements in the anatomical,
structural, functional, and architectural signatures of the
otherwise cirrhotic livers. The eﬃcacy in protecting the liver
was however marginally better with the higher BR dose,
and encouragingly very close to that of silymarin. Nearly
identical responses between the high-dose BR and silymarin
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Figure 6: Eﬀect of the BR extract on the level of MDA in the liver tissue. Data were expressed as Mean ± SEM. Means between the silymarin
treated Group 3, low-dose BR-treated Group 4, and high-dose BR-treated Group 5 had significant diﬀerences when compared with the
cirrhosis control Group 2 with ∗P < 0.001 and compared with the normal control Group 1 with ∗∗P < 0.001.
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Figure 7: Eﬀect of BR ethanol group on SOD level in the liver tissue. Data are expressed as mean ± SEM. Means among groups (n = 6
rate/group) show significant diﬀerence, ∗P < 0.001 compared to cirrhosis control group, and ∗∗P < 0.001 compared to normal control
group.
treatments can be explained by the anti-oxidant powers of
the two extracts, as asserted by the FRAP measurements in
Figure 1.
In the treated rats, the rise of the serum levels of
ALT, AST, AP, LDH, and bilirubin and the decline in the
levels of albumin and total protein were prevented. The
trends in restoring the balance in serum chemicals may be
attributed to the capacity of the BR extract to regulate the
hepatic antioxidant status or to directly participate in the
radical scavenging process [34]. In the TAA metabolism,
anti-oxidants work against oxidative stress by scavenging the
byproduct TASO2 and, thereby, reducing the magnitude of
the impact on the liver. Phenol compounds are very eﬀective
anti-oxidants with strong free radical-scavenging abilities
[35]. Flavonoids are polyphenols and used in treating many
diseases including liver cirrhosis. Flavonoids (Kaempferol
and Quercetin) are present in the plant BR and therefore
likely be responsible for the membrane stabilizing activities
demonstrated by the observed reductions in the serum levels
of the liver enzymes. The lowered bilirubin levels meant
the presence of more stable erythrocyte plasma membranes.
This consequently implied that the BR extract stabilized the
hepatocyte membranes and hence interrupted the release of
the liver enzymes into the blood [36]. The inhibitory eﬀect of
BR extract on the lipid peroxidation of the macromolecules
in the membrane can again be credited to the scavenging
eﬀect of the flavonoid content of the plant [37].
5. Conclusions
The progression of the liver cirrhosis induced by TAA in rats
can be inhibited using ethanol-based BR extract. Specifically,
this natural extract has the power to protect the liver by
preventing the cascade of harmful events in liver cirrhosis.
The eﬀects are comparable to those of silymarin (50mg/kg)
when the corresponding daily dose was 500mg/kg. The
capability of the BR extract to preserve the liver status quo
of property, structure, and function against toxic exposure is
encouraging and warrants further studies. The significance
of its pharmacologic potential in successfully treating liver
cirrhosis can be explored by mapping the molecular path-
ways of its action in the future.
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